Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02745392 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
A Phase 2 study of Acute Migraine, sponsored by Zosano Pharma Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 365
- Enrollment target
- 20
- Study locations
NCT02745392: Completed Phase 2 study of Acute Migraine, sponsored by Zosano Pharma Corporation.
NCT02745392 is a Phase 2 study of Acute Migraine that has completed, run by Zosano Pharma Corporation. The registered enrollment target is 365 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (174% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02745392, a Phase 2 study of Acute Migraine, has completed, sponsored by Zosano Pharma Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 365 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
Primary Outcome
Pain Freedom at 2 hours post study drug administration is one of the co-primary endpoints. Subjects were queried via their eDiary about their level of migraine pain (none, mild, moderate, or severe) at various intervals post-dose. Subjects who answered none at 2 hours post study drug were considered pain free at 2 hours.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ZP-Zolmitriptan
Study Locations (20)
California
- The Research Center of Southern California - Carlsbad
- Allergy and Asthma Specialists Medical Group and Research Center - Huntington Beach
- Downtown LA Research Center - Los Angeles
- Allergy & Asthma Associates of Southern California - Mission Viejo
- Allergy and Asthma Associates of Santa Clara Valley Research Center - San Jose
- California Medical Clinic for Headache - Santa Monica
- Empire Clinical Research - Upland
Massachusetts
- Boston Clinical Trials - Boston
- Novex Medical Research - New Bedford
- Northeast Medical Research Associates, Inc. - North Dartmouth
- MedVadis Research Corporation - Watertown
Florida
- Avail Clinical Research, LLC - DeLand
- Medical Research Group of Central Florida - Orange City
- Meridien Research - Tampa
Michigan
- Michigan Head Pain &Neurological Institute - Ann Arbor
- Westside Family Medical Center, P.C - Kalamazoo
Arizona
- Clinical Research Advantage, Inc./Thunderbird Internal Medicine - Glendale
Colorado
- Colorado Allergy & AsthmaCenters, PC - Denver
Connecticut
- Ki Health Partners - Stamford
Georgia
- Clinical Research Atlanta - Stockbridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
What the finished NCT02745392 record still lists
NCT02745392 is an interventional study that assigns participants to a tested intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (174% higher).
The record links to 1 condition, with Acute Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02745392 names 20 study sites across 8 states, led by California, Massachusetts, Florida.
Frequently Asked Questions
What is clinical trial NCT02745392 about?
NCT02745392 is a clinical study titled "Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine". This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
What is the current status of trial NCT02745392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 365 participants. The study started on 2016-06. Estimated completion is 2017-01.
What conditions does trial NCT02745392 study?
This clinical trial studies the following conditions: Acute Migraine.
What interventions are being tested in trial NCT02745392?
The interventions under investigation include: Placebo (DRUG), ZP-Zolmitriptan (DRUG).
Who is sponsoring clinical trial NCT02745392?
This trial is sponsored by Zosano Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02745392 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02745392's enrollment target sits among peer trials
365 121st of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05592626 · 365 participants · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia